Please login to the form below

Not currently logged in

SoftBank buys $5bn stake in Roche

The Japanese conglomerate is betting on Roche becoming a £1tr company

Roche Basel Switzerland

Softbank Group, Japan’s second largest public company, has bought $5bn of Roche’s non-voting stock, making it one of the company’s largest investors.

The stock purchase was made through a unit responsible for the ‘Nasdaq whale’ trade last year, which saw the purchase of billions of dollars of US equity derivatives. The trade was masterminded by former Deutsche Bank trader Akshay Naheta through his company, SB Northstar, which has been behind some of SoftBank’s most controversial investments.

However, the Roche purchase comes just months after SoftBank founder, Masayoshi Son, announced he would slash investments by SB Northstar after losses of $5.6bn since it was set up in July 2020.

Until now, SB Northstar’s investment focus has been on tech and early stage biotech, so the purchase of a substantial stake in a large pharmaceutical company has surprised many.

The deal has not been confirmed publicly by SoftBank or Roche butthose close to the dealreport that it is motivated by Roche’s diverse portfolio as a simple bet on the company’s share price. It is reported that SB Northstar is convinced that Roche can grow from its current $380bn market value into a $1tn company.

SoftBank also believes Roche’s Genentech division – focused on data-based drug discovery and development – is undervalued.

Shares of the Basel-based company have risen 18% this year, following a drop in sales during the pandemic. Strong demand for its COVID-19 tests saw Roche’s diagnostics sales grew 51% in the first half of 2021, to make up about a third of the group’s overall revenues of SFr31bn ($34bn). Its rheumatoid arthritis drugs, Actemra, has also been repurposed to treat severe COVID-19 patients and is recommended by the World Health Organization, while the company has developed a COVID-19 antibody treatment with US company Regeneron.

A bounceback in routine treatment following the pandemic has also helped the company return to growth.

Roche has a dual-class share structure with both voting and non-voting shares. The founding families own 50.1% of the voting class, while rival Novartis holds one-third.

Article by
Hugh Gosling

5th August 2021

From: Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
Springer Nature

Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...